MétaCan
Menu
Back to cohort
Record W3018861031 · doi:10.1136/bmjopen-2019-035959

[ <sup>18</sup> F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial

2020· article· en· W3018861031 on OpenAlexafffundabout
Rachel Glicksman, Ur Metser, John F. Valliant, Peter Chung, Neil Fleshner, Robert G. Bristow, David Green, Antonio Finelli, Robert J. Hamilton, Teodor Stanescu, Douglas Hussey, Charles Catton, Mary Gospodarowicz, Padraig Warde, Andrew Bayley, Stephen Breen, Doug Vines, David A. Jaffray, Alejandro Berlín

Bibliographic record

VenueBMJ Open · 2020
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsSunnybrook Health Science CentrePrincess Margaret Cancer CentreMcMaster UniversityWomen's College HospitalCentre for Probe Development and CommercializationUniversity of TorontoUniversity Health NetworkHealth Sciences CentreMount Sinai Hospital
FundersAstellas PharmaTerry Fox Research InstituteUniversity of TorontoAssociation of Canadian Universities for Research in AstronomyPrincess Margaret Cancer FoundationCanadian Association of Radiation Oncology
KeywordsMedicineAblative caseProstate cancerProtocol (science)Clinical trialMedical physicsNuclear medicineRadiation therapyCancerRadiologyInternal medicinePathologyAlternative medicine

Abstract

fetched live from OpenAlex

Introduction The oligometastatic (OM) disease hypothesis of an intermediate metastatic state with limited distant disease deposits amenable for curative therapies remains debatable. Over a third of prostate cancer (PCa) patients treated with radical prostatectomy and postoperative radiotherapy experience disease recurrence; these patients are considered incurable by current standards. Often the recurrence cannot be localised by conventional imaging (CT and bone scan). Combined anatomical imaging with CT and/or MR with positron emission tomography (PET) using a novel second-generation prostate-specific membrane antigen (PSMA) probe, [ 18 F]DCFPyL, is a promising imaging modality to unveil disease deposits in these patients. A new and earlier molecularly defined oligorecurrent (OR) state may be amenable to focal-targeted ablative curative-intent therapies, such as stereotactic ablative radiotherapy (SABR) or surgery, thereby significantly delaying or completely avoiding the need for palliative therapies in men with recurrent PCa after maximal local treatments. Methods and analysis This ongoing single-institution phase II study will enrol up to 75 patients total, to include up to 37 patients with response-evaluable disease, who have rising prostate-specific antigen (range 0.4–3.0 ng/mL) following maximal local therapies with no evidence of disease on conventional imaging. These patients will undergo [ 18 F]DCFPyL PET-MR/CT imaging to detect disease deposits, which will then be treated with SABR or surgery. The primary endpoints are performance of [ 18 F]DCFPyL PET-MR/CT, and treatment response rates following SABR or surgery. Demographics and disease characteristics will be summarised and analysed descriptively. Response rates will be described with waterfall plots and proportions. Ethics and dissemination Ethics approval was obtained from the institutional Research Ethics Board. All patients will provide written informed consent. [ 18 F]DCFPyL has approval from Health Canada. The results of the study will be disseminated by the principal investigator. Patients will not be identifiable as individuals in any publication or presentation of this study. Trial registration numbers NCT03160794

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.007
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.014
Threshold uncertainty score0.048

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0070.004
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0010.001
Science and technology studies0.0010.003
Scholarly communication0.0020.001
Open science0.0030.001
Research integrity0.0040.005
Insufficient payload (model declined to judge)0.0140.006

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.287
GPT teacher head0.538
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations10
Published2020
Admission routes3
Has abstractyes

Explore more

Same venueBMJ OpenSame topicProstate Cancer Treatment and ResearchFrench-language works237,207